About the Company: AstraZeneca is a global #biopharma leader Strong presence in rare diseases and immunology About the Product (#Ultomiris): Complement inhibitor therapy Designed for #immune-mediated kidney disease Key Highlights: Breakthrough #Phase3 data Advancing #nephrology "Congratulations to AstraZeneca." Michel Demar,Aradhana Sarin,Philip Broadley,Euan Ashley,Birgit Conix,Ruud Dobber,David Fredrickson,Susan Galbraith Innovation is transforming kidney disease treatment. #Pharma #Nephrology #HealthcareInnovation FDA The National Institutes of Health Centers for Disease Control and Prevention ISO - International Organization for Standardization World Health Organization European Medicines Agency International Society of Nephrology American Society of Nephrology International Federation of Pharmaceutical Manufacturers & Associations || cGxP.wire || cGxP.Directory || cGxP.jobs || cGxP.Tech || To view or add a comment, sign in I've just been reading about Boehringer Ingelheim's exciting developments in the obesity treatment space

The chemokine fractalkine can activate integrins without CX3CR1 through direct binding to a ligand-binding site distinct from the classical RGD-binding site
What Conditions does A B12 Injection Treat
Yes, its a critical factor
With the correct workflow, your anemia claims stay clean, supported, and paid the first time
Hyperhomocysteinemia as a risk factor for arterial and venous disease